Abstract
Purpose of Review
The goal of this review is to summarize recent advances in the field and highlight important new insights from the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial regarding the optimal management of patients with renal artery stenosis (RAS).
Recent Findings
The CORAL trial demonstrated that subjects with RAS had similar outcomes whether randomized to optimal medical therapy alone or optimal medical therapy plus renal artery stenting. Subgroup analyses have failed to demonstrate that baseline blood pressure or lesion gradients can predict which subjects may have improved response after stent intervention. Importantly, urine albumin to creatinine ratio appears to different subjects that may benefit from stent intervention versus subjects that are unlikely to achieve any benefit. In addition, there was a trend toward increase benefit in subjects with greater percent stenosis.
Summary
Atherosclerotic RAS is a frequent finding and is often seen in patients with resistant hypertension, congestive heart failure, chronic kidney disease, and rarely those who need renal replacement therapy. Risk factors for RAS overlap with those of generalized atherosclerosis including hyperlipidemia, smoking, hypertension, and diabetes. Patients with CAD or PVD frequently have co-existing RAS. The management of RAS has been controversial for many years. The CORAL trial provides important insights into the optimal management of subjects with RAS.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
Derkx FH, Schalekamp MA. Renal artery stenosis and hypertension. Lancet. 1994;344(8917):237–9.
Harding MB, Smith LR, Himmelstein SI, Harrison K, Phillips HR, Schwab SJ, et al. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol. 1992;2(11):1608–16.
Olin JW, Melia M, Young JR, Graor RA, Risius B. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med. 1990;88(1N):46N–51N.
Rihal CS, Textor SC, Breen JF, McKusick MA, Grill DE, Hallett JW, et al. Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc. 2002;77(4):309–16. doi:10.1016/S0025-6196(11)61782-5.
Blum U, Krumme B, Flugel P, Gabelmann A, Lehnert T, Buitrago-Tellez C, et al. Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. N Engl J Med. 1997;336(7):459–65. doi:10.1056/NEJM199702133360702.
Burket MW, Cooper CJ, Kennedy DJ, Brewster PS, Ansel GM, Moore JA, et al. Renal artery angioplasty and stent placement: predictors of a favorable outcome. Am Heart J. 2000;139(1 Pt 1):64–71.
van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med. 2000;342(14):1007–14. doi:10.1056/NEJM200004063421403.
Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med. 2009;150(12):840–8. W150-1
•• Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370(1):13–22. doi:10.1056/NEJMoa1310753. An optimal medical therapy achieved similar outcomes as optimal medical therapy plus stent intervention in the CORAL randomized controlled trial of subjects with renal artery stenosis.
AbuRahma AF, Srivastava M, Mousa AY, Dearing DD, Hass SM, Campbell JR, et al. Critical analysis of renal duplex ultrasound parameters in detecting significant renal artery stenosis. J Vasc Surg. 2012;56(4):1052–1059, 60 e1; discussion 9-60. doi:10.1016/j.jvs.2012.03.036.
Mangiacapra F, Trana C, Sarno G, Davidavicius G, Protasiewicz M, Muller O, et al. Translesional pressure gradients to predict blood pressure response after renal artery stenting in patients with renovascular hypertension. Circ Cardiovasc Interv. 2010;3(6):537–42. doi:10.1161/CIRCINTERVENTIONS.110.957704.
Drieghe B, Madaric J, Sarno G, Manoharan G, Bartunek J, Heyndrickx GR, et al. Assessment of renal artery stenosis: side-by-side comparison of angiography and duplex ultrasound with pressure gradient measurements. Eur Heart J. 2008;29(4):517–24. doi:10.1093/eurheartj/ehm631.
O'Connor PM. Renal oxygen delivery: matching delivery to metabolic demand. Clin Exp Pharmacol Physiol. 2006;33(10):961–7. doi:10.1111/j.1440-1681.2006.04475.x.
Bittl JA. Damage control for renal artery stenting. Circulation. 2008;117(21):2724–6. doi:10.1161/CIRCULATIONAHA.108.776732.
Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension : I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59(3):347–79.
Laird JR, Tehrani F, Soukas P, Joye JD, Ansel GM, Rocha-Singh K. Feasibility of FiberNet® embolic protection system in patients undergoing angioplasty for atherosclerotic renal artery stenosis. Catheter Cardiovasc Interv. 2012;79(3):430–6. doi:10.1002/ccd.23292.
Cooper CJ, Haller ST, Colyer W, Steffes M, Burket MW, Thomas WJ, et al. Embolic protection and platelet inhibition during renal artery stenting. Circulation. 2008;117(21):2752–60. doi:10.1161/CIRCULATIONAHA.107.730259.
Chen S, Ge Y, Si J, Rifai A, Dworkin LD, Gong R. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int. 2008;74(9):1128–38. doi:10.1038/ki.2008.380.
Yu C, Gong R, Rifai A, Tolbert EM, Dworkin LD. Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. J Am Soc Nephrol. 2007;18(3):750–9. doi:10.1681/ASN.2006070770.
•• Murphy TP, Cooper CJ, Matsumoto AH, Cutlip DE, Pencina KM, Jamerson K, et al. Renal artery stent outcomes: effect of baseline blood pressure, stenosis severity, and translesion pressure gradient. J Am Coll Cardiol. 2015;66(22):2487–94. doi:10.1016/j.jacc.2015.09.073. Surprisingly, many of the conventional baseline variables thought to predict improved response to stent intervention were not predictive of response in the CORAL trial. Baseline blood pressure and lesion gradients did not predict response to stent intervention. There was a trend toward greater benefit with stent intervention among subjects with greater percent stenosis, but this was non-significant.
•• Murphy TP, Cooper CJ, Pencina KM, D'Agostino R, Massaro J, Cutlip DE, et al. Relationship of albuminuria and renal artery stent outcomes: results from the CORAL randomized clinical trial (cardiovascular outcomes with renal artery lesions). Hypertension. 2016;68(5):1145–52. doi:10.1161/HYPERTENSIONAHA.116.07744. This study demonstrated that albuminuria has a significant impact on likelihood of benefit from stent intervention. Subjects with below median values of albuminuria had improved benefit with renal artery stent intervention.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Rajesh Gupta and Salem Assiri declare that they have no conflict of interest.
Christopher J. Cooper reports grants from NIH and Pfizer, grants and other from AstraZeneca, and grants and other from Cordis.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Peripheral Vascular Disease
Rights and permissions
About this article
Cite this article
Gupta, R., Assiri, S. & Cooper, C.J. Renal Artery Stenosis: New Findings from the CORAL Trial. Curr Cardiol Rep 19, 75 (2017). https://doi.org/10.1007/s11886-017-0894-2
Published:
DOI: https://doi.org/10.1007/s11886-017-0894-2